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The development of an accurate, practical, and affordable diagnostic test is essential to improve the
management of visceral leishmaniasis (VL) in remote health centers. We evaluated the Formol Gel test (FGT)
and two rK39 antigen-based dipsticks, the DUAL-IT L/M, and the Kalazar Detect for VL diagnosis in Amudat
Hospital in Uganda. The DUAL-IT L/M was also evaluated for the diagnosis of malaria. All patients clinically
suspect of VL were prospectively included in the study between October 2003 and March 2004. The gold
standard used to deﬁne a VL case was a positive spleen aspirate or a direct agglutination test titer of >1:12,800
with an appropriate clinical response to antileishmanial therapy. A total of 131 VL and 112 non-VL patients
were included in the analysis. The DUAL IT L/M was found to be more sensitive than the Kalazar Detect: 97%
(95% conﬁdence interval [95%CI]  92 to 99%) versus 82% (95%CI  74 to 87%). The Kalazar Detect and the
DUAL IT L/M were highly speciﬁc (99% [95%CI  95 to 100%] and 97% [95%CI  92 to 99%], respectively).
The FGT lacked both sensitivity (66% [95%CI  57 to 73%]) and speciﬁcity (90% [95%CI  83 to 94%]). The
sensitivity of the DUAL IT L/M for malaria was only 57% (95%CI  37 to 76%). The two rK39 dipsticks can
be used for diagnostic conﬁrmation of VL in this region. The DUAL-IT L/M without its malaria diagnostic
component (DiaMed-IT LEISH) will be adopted as ﬁrst-line test for VL in Uganda.
Visceral leishmaniasis (VL) or kala-azar affects an estimated
500,000 persons yearly, predominantly in the poor rural areas
of India, Bangladesh, Nepal, Sudan, and Brazil (10). Most
patients present with prolonged fever, weight loss, and spleno-
megaly. Other tropical diseases such as malaria, disseminated
tuberculosis, or enteric fever can share the same clinical pre-
sentation. Therefore, laboratory testing is necessary to conﬁrm
the diagnosis of VL. Diagnostic tests for VL need to be highly
sensitive and speciﬁc because of the fatal evolution of the
disease without adequate treatment and the serious toxicity of
antimonials (18), the most commonly used ﬁrst-line therapy.
Moreover, tests must be cheap and easy-to-perform since VL
occurs in poor and remote rural communities with limited
access to referral hospitals. The development of diagnostic
tests for improved case management of VL has been rated as
one of the most needed among the infectious diseases preva-
lent in the developing world (13).
Direct microscopic examination of spleen aspirates is con-
sidered the gold standard for VL diagnosis, but both the aspi-
ration procedure and the reading of slides require a high level
of expertise that makes it unsuitable for generalized ﬁeld use.
Lymph node and bone marrow aspirates are alternative pro-
cedures but lack sensitivity (26). Serological tests have been
developed to replace parasitological diagnosis in the ﬁeld. The
Direct Agglutination Test (DAT), developed in the 1980s (11,
12), has been validated in several areas of endemicity (1–3, 5).
Unfortunately, the relative sophistication of the DAT proce-
dure (e.g., need for micropipettes and microtitration plates)
restricts its use to referral hospitals or well-supported health
centers.
Simpler tests designed for ﬁeld use exist. The Formol Gel
Test (FGT) is a cheap, easy to perform but poorly sensitive test
based on the detection of polyclonal immunoglobulins. The
FGT remains the sole test available for VL diagnosis in many
peripheral health centers in East Africa or in the Indian sub-
continent (8). Recently, serological testing based on the detec-
tion of antibodies against a recombinant antigen derived from
a 39-amino-acid repeat in Leishmania chagasi (rK39) was de-
veloped into a dipstick format. Validation studies have shown
variable results depending on the location of the study site, the
brand of the dipstick, and the study methodology (5–7, 9, 17,
19, 22, 27). Various brands of rK39 dipsticks have been eval-
uated in Sudan (16, 22, 27), but no validation studies have been
published from other African countries. Since malaria is always
present in the differential diagnosis of VL in Africa, a dipstick
detecting both antibodies to rK39 antigen (for VL diagnosis)
and speciﬁc plasmodial LDH (pLDH; for malaria diagnosis)
was also recently developed (DUAL-IT L/M dipstick from
DiaMed AG, Switzerland).
In Uganda, the area of endemicity of VL is restricted to
Pokot County in the northeastern part of the country (24). This
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5973endemic focus continues eastward in the West Pokot District
of Kenya. Me ´decins Sans Frontie `res (MSF) has supported the
clinical management of suspect VL patients in Amudat Hos-
pital (AH) since 1997. The DAT and spleen aspiration were
introduced in AH in 2000, and the DAT diagnostic thresholds
(negative, borderline, positive) were validated in 2001 (unpub-
lished data). However, cheaper and more practical diagnostic
tests are needed to ensure a sustainable access to VL diagnosis
in AH after the withdrawal of MSF support. Therefore, we
conducted a diagnostic accuracy study in AH, comparing the
performance of the FGT and two marketed rK39 dipsticks.
MATERIALS AND METHODS
Study area and population. The study was conducted in AH, a 120-bed hos-
pital located in Pokot County, Nakapiripirit District, in northeastern Uganda.
The aim was to enroll at least 100 true cases of VL and 100 true non-VL cases
in the study to achieve adequate precision for the estimation of both the sensi-
tivity and the speciﬁcity of the tests. The total sample size was ﬁxed at 300 clinical
suspects, taking into account an expected proportion of 40% true VL cases
among clinical suspects.
Clinical suspect patients were deﬁned as patients with a history of fever of 14
days with either clinical splenomegaly or wasting syndrome. All clinical suspect
patients, adult and pediatric, who presented at the Outpatient Department of
AH between October 2003 and March 2004 were eligible for the study. Consent
was documented by signature of the written informed consent form by the
patient or her or his tutor (for patients younger than 15 years old). All patients
were guaranteed access to free care in AH. Patients were advised to come back
to AH in case of recurrence of symptoms. The study protocol was approved by
the Uganda National Ethics Committee Board in September 2003.
Laboratory investigations. The diagnostic work-up of all patients included in
the study followed the diagnostic algorithm routinely in use at AH (Fig. 1).
Personal and medical characteristics of the patient were recorded in a case
reporting form. In the laboratory, 5 ml of blood was drawn by venous puncture.
Two ﬁlter papers were impregnated, and the remaining blood was left to sedi-
ment. The plasma was collected to perform the DAT, the FGT, and the Kalazar
Detect dipstick (InBios International, Inc., Seattle, Wash.). An additional few
drops of blood were obtained by ﬁnger pricking to perform the hemoglobin
count, the DUAL-IT L/M dipstick (DiaMed AG, Switzerland) and the thick and
thin smear for qualitative and quantitative assessment of Plasmodium falciparum
and other Plasmodium species. The dipsticks were stored at room temperature
that ranged between 24 to 32°C during the study duration.
Tests procedures. the spleen aspirate was performed by the physician in charge
of the patient. The spleen material was spread on a glass slide, stained with
Giemsa solution, and examined microscopically by an experienced laboratory
technician. The DAT was performed by the same laboratory technician accord-
ing to the method of Harith et al. (11). The FGT, the Kalazar Detect, and the
DUAL IT L/M were performed on the day of plasma collection by another
laboratory technician who was blinded to the results of both the DAT and the
spleen aspiration. The results of the tests under evaluation were recorded on a
separate log book and were not used by physicians for any decision regarding the
management of the patient.
The FGT was performed by adding 20 l of 40% formaldehyde to 200 lo f
serum in a glass tube. The geliﬁcation reaction was observed after 30 min. The
test was considered positive if a clot was seen at the bottom of the tube. The
Kalazar Detect and the DUAL-IT L/M were performed according to manufac-
turers’ instructions. The result of the tests was reported as positive or negative.
For both tests, even a faint reactive line was considered positive.
Quality control. all thick and thin smears were kept in a separate box, trans-
ported to the Malaria Research Laboratory of Mbarara Hospital in Uganda and
examined by laboratory technicians experts in malaria diagnosis. Blood-impreg-
nated ﬁlter papers were sent for quality control of the DAT to the Royal Institute
of Tropical Medicine in Amsterdam, Holland. All slides of spleen aspirates were
cross-checked at the Laboratory of Parasitology of the Geneva University Hos-
pital (GUH). Slides with discrepant results between AH and GUH were sent for
identiﬁcation by PCR analysis at the Swiss Tropical Institute in Basel, Switzer-
land (14).
Case deﬁnitions. A case of VL was deﬁned as a patient with a positive spleen
aspirate in two laboratories (by microscopic reading at AH and/or GUH or by
PCR at the Swiss Tropical Institute) or as a patient with a DAT titer of 1:
12,800 with an adequate clinical response to antimonial therapy (resolution of
fever, improvement of general condition, and decreased spleen size at the end of
treatment). A non-VL case was deﬁned as a patient with a DAT titer of 1:1,600
or as a patient with a borderline DAT titer (1:1,600 to 1:12,800) with a negative
spleen puncture conﬁrmed in two laboratories with no diagnosis of VL made
during the six following months. A malaria case was deﬁned as a patient with a
positive thick and thin smear examination at Mbarara Hospital laboratory,
whereas a negative smear examination deﬁned a nonmalaria case.
Data management and statistical analysis. Data from the case reporting form
were entered in an Excel data sheet and later cross-checked by the principal
investigator. The data were analyzed with SPSS 11.0 for Windows version (SPSS,
Inc., Chicago, Ill.). Numerical variables were summarized by mean and standard
deviation if normally distributed and, if they were not, by median and quartiles.
Categorical variables were compared by using cross-tabulations and chi-square
tests, whereas numerical variables (means) were compared to the Student t test,
at a critical -level of 0.05. All P values were two sided. Sensitivity, speciﬁcity,
positive and negative predictive values, and their exact 95% binomial conﬁdence
intervals (95%CI) were calculated for the FGT and the two rK39 dipstick tests
from the groups of VL and non-VL patients by using the Conﬁdence Interval
Analysis software for Windows.
RESULTS
Diagnostic accuracy of diagnostic tests for VL. A total of 276
clinical suspect patients were enrolled in the study between
October 2003 and March 2004. Thirty-three patients were ex-
cluded from the analysis for the following reasons: failure to
meet the deﬁnition of clinical suspect (21 patients), a differ-
ence of more than two dilution titers between AH and the
Royal Institute of Tropical Medicine in Amsterdam, Holland,
laboratories (10 patients), or death before completion of diag-
nostic investigations (one patient) or antileishmanial treatment
(one patient). A total of 243 patients, 131 with VL (54%) and
112 with another diagnosis (46%), were included in the anal-
ysis. The demographic and clinical characteristics of the 131
VL and 112 non-VL patients are compared in Table 1. VL was
FIG. 1. Diagnostic algorithm of visceral leishmaniasis in Amudat
Hospital, Pokot County.
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by a DAT of 1:25,600 with a good response to antileishma-
nial treatment in 116 patients (89%). The ﬁnal diagnosis of the
112 non-VL patients was hyper-reactive malarial splenomegaly
in 68 patients (61%), smear-proven malaria in 17 patients
(15%), brucellosis in 8 patients (7%), liver disease in 3 patients
(3%), and another or unknown illness in 16 patients (14%).
None of the initially diagnosed non-VL patients were diag-
nosed with VL within a 6-month period after discharge from
AH.
The DUAL IT L/M was signiﬁcantly more sensitive than the
Kalazar Detect: 97% (95%CI  92 to 99%) versus 82%
(95%CI  74 to 87%) (Table 2). The Kalazar Detect and the
DUAL IT L/M were both highly speciﬁc: 99% (95%CI  95 to
100%) and 97% (95%CI  92 to 99%), respectively. The FGT
lacked both sensitivity (66% [95%CI  57 to 73%]) and spec-
iﬁcity (90% [95%CI  83 to 94%]). The performance of the
tests was not signiﬁcantly inﬂuenced by the mode of conﬁrma-
tion of VL diagnosis (data not shown).
Diagnostic accuracy of the DUAL IT L/M for malaria. Of
the 276 patients enrolled in the study, 26 were excluded from
analysis for the following reasons: failure to meet the deﬁnition
of clinical suspect for VL (21 patients), thick and thin smear
not available for examination at Mbarara laboratory (4 pa-
tients), or death before completion of diagnostic tests (1 pa-
tient). Of the remaining 250 patients, 21 (8.4%) had smear
proven malaria, whereas 229 patients (91.6%) had a negative
smear. Previous treatment of malaria within 2 weeks of admis-
sion was mentioned by 30 (12%) patients. A low parasitemia
(200 parasites/mm
3) was found in nine (43%) of the positive
cases. The sensitivity and speciﬁcity of the DUAL IT L/M for
the diagnosis of malaria were, respectively, 57% (95%CI  37
to 76%) and 86% (95%CI  81 to 90%). We found a trend
toward a higher sensitivity in patients with 200 parasites/mm
3
at 83% (95%CI  55 to 95%) compared to patients with 200
parasites/mm
3 at 22% (95%CI  6 to 55%). The performance
of the test was not signiﬁcantly affected by a history of previous
antimalarial treatment before admission.
DISCUSSION
The DUAL IT L/M rK39 antigen-based dipstick from Dia-
Med AG, Switzerland, was found to be highly sensitive (97%)
and speciﬁc (97%) for the diagnosis of VL in northeastern
Uganda. The Kalazar Detect dipstick was also highly speciﬁc
(99%) but substantially less sensitive (82%). The FGT was less
sensitive (66%) and speciﬁc (90%) than the rK39 dipsticks.
Our study is the ﬁrst to evaluate the performance of these
tests in Uganda and is one of the few diagnostic accuracy
studies in VL using a prospective design in a clinical setting
TABLE 1. Demographic and clinical characteristics of the 131 VL and 112 non-VL patients included in the diagnostic tests validation study
in Amudat Hospital, Uganda
Characteristic
No. (%) or mean (SD)
a
P
VL patients (n  131) Non-VL patients (n  112)
Gender 0.001
Female 35 (27) 53 (47)
Male 96 (73) 59 (53)
Age 13.6 (11.1) 16.2 (12.5) 0.09
Country of residence 0.01
Uganda 36 (28) 54 (48)
Kenya 95 (72) 58 (52)
Previous treatment for VL 0 6 (6) 0.004
Symptoms (self-reported)
Abdominal pain or swelling 125 (95) 102 (91) 0.17
Cough 89 (68) 59 (53) 0.015
Wt loss 40 (31) 22 (20) 0.052
Epistaxis 17 (13) 16 (14) 0.77
Headaches 65 (50) 47 (42) 0.23
Anorexia 21 (16) 22 (20) 0.46
Peripheral edema 8 (6) 3 (3) 0.2
Duration of fever (wk) 7.9 (9.4) 12 (17.1) 0.02
Spleen size from costal margin (cm) 13.8 (4.3) 13.2 (5) 0.33
Hemoglobin count (g/dl) 7.8 (1.7) 9.2 (1.7) 0.001
Smear-proven malaria 1 (1) 20 (18) 0.001
a Values indicate number of patients (%) except as noted.
TABLE 2. Sensitivity, speciﬁcity, positive and negative predictive values of the DiaMed-DUAL IT L/M, Kalazar Detect, and FGT for
diagnosis of VL in Amudat, Uganda
Diagnostic test
% (95% CI)
Sensitivity Speciﬁcity Positive predictive value Negative predictive value
DUAL-IT L/M 97 (92–99) 97 (92–99) 98 (93–99) 97 (91–99)
Kalazar Detect 82 (74–87) 99 (95–100) 99 (95–100) 82 (75–88)
Formol Gel Test 66 (57–73) 90 (83–94) 89 (81–94) 69 (61–76)
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case ascertainment was based either on direct examination of
Giemsa-stained splenic aspirates smears (close to 100% sensi-
tivity and speciﬁcity) or on a combination of serology with
observation of response to treatment. The diagnostic accuracy
of DAT is known to be excellent and, since the therapeutic
spectrum of antimonials is so narrow, a good response to it can
safely be regarded as evidence of visceral leishmaniasis (25).
All DAT results and spleen aspirates were reviewed in refer-
ence laboratories, and patients with discordant results were
excluded from analysis. Therefore, we can safely claim that
little or no misclassiﬁcation occurred in the present study with
regard to disease status.
The DiaMed-IT LEISH, the equivalent of the DUAL IT
L/M but without the malaria diagnostic component, has been
previously evaluated in India and Sudan. In India, the sensi-
tivity of the DiaMed-IT LEISH was 99% and its overall spec-
iﬁcity was 94% when tested on blood from patients with VL,
patients with other diseases, and controls from areas of high
and low endemicity (20). In Sudan, the DiaMed-IT LEISH was
found to be 81% sensitive and 97% speciﬁc in a group of 341
clinical suspect individuals (16). Low sensitivity of rK39 anti-
gen-based dipsticks was already reported in another study from
Sudan, and the authors of that study suggested that Sudanese
VL patients develop lower titers of antibodies against the K39
antigen (27). Other researchers suggest that the format of the
immunochromatographic assay might be the cause (16).
Therefore, we believe that the results of diagnostic accuracy
studies for VL should only be extrapolated with caution be-
tween different epidemiological and ecological regions.
The Kalazar Detect dipstick from Inbios International, Inc.,
Seattle, Wash., has been previously evaluated (sometimes un-
der another trade name) in the Indian subcontinent and Latin
America, with reported sensitivities and speciﬁcities of 87 to
100% and 71 to 100%, respectively (5–7, 9, 19). The present
study is the ﬁrst published evaluation of the validity of the
Kalazar Detect among African patients clinically suspect of
VL. We found a disappointingly low sensitivity (81%) but an
excellent speciﬁcity (99%). An ongoing multicenter diagnostic
study conducted by the World Health Organization in several
East African countries will add data on the validity of the
Kalazar Detect. According to the manufacturer, a more sensi-
tive generation of the Kalazar Detect dipstick is under devel-
opment.
The poor sensitivity of the FGT conﬁrmed the ﬁndings of
previous studies (5, 8). The speciﬁcity of the FGT was good
(90%) but lower than recently described in Nepal (5), most
likely because hyper-reactive malarial syndrome, a classical
cause of polyclonal hypergammaglobulinemia, was a frequent
diagnosis (61%) in our non-VL patients. We considered the
diagnostic performance of the FGT in this setting insufﬁcient
to recommend its use. Eleven percent of persons with a posi-
tive FGT would be wrongly started on antileishmanial therapy,
an unacceptable proportion considering the heavy burden on
the patient of 1 month of parenteral therapy and the relative
toxicity and high cost of branded antimonials (Pentostam), the
current ﬁrst-line treatment in use in Uganda. Also, 34% of true
kala-azar patients would be missed by the FGT, an unaccept-
ably high proportion.
Practical issues in the utilization of the two rK39 dipsticks
also need to be considered. A major advantage of the DUAL
IT L/M is that it can be performed with blood obtained by
ﬁngerprick. Moreover, all test components are included in
individual packages. In contrast, the Kalazar Detect is per-
formed with serum, requiring sampling of venous blood and
extra materials such as a micropipette and test tubes. Another
advantage of the DUAL IT L/M is that the test result remains
stable and can be read up to several months later. This allows
for external quality control when the test is performed at pe-
ripheral health units by workers with limited training. Accord-
ing to the manufacturers, the cost per unit of the Kalazar
Detect and the DUAL IT L/M dipsticks for developing coun-
tries is $1.00 and $1.30 (U.S. dollars), respectively. This rep-
resents a very small fraction of the total expenses needed to
manage patients with VL since the cost of test and treatment
strategies depends mainly on the cost of hospitalization and
treatment (4). The relatively high packaging volume of the
DUAL IT L/M can indirectly increase transport cost if high
numbers of dipsticks are needed.
We found no added value of the malaria antigen (pLDH)
detection line present on the DUAL IT L/M in our population
of VL suspect patients. Only few non-VL patients were diag-
nosed with smear-proven malaria (8.4%), and the sensitivity of
the DiaMed DUAL IT L/M among these patients was only
57%. This poor sensitivity was most likely due to the high
proportion (43%) of patients with low parasitemia (200 par-
asites/mm
3). A low sensitivity of the Optimal test (DiaMed
AG, Switzerland), using the same technology, has been previ-
ously reported in malaria patients with low parasitemia (15,
21). It must be emphasized that malaria has a clear seasonal
pattern in the study area and that our study took place during
a low-transmission season. The prevalence of smear-proven
malaria and the intensity of parasitemia is likely to be higher
during the high-transmission rainy season, thus inﬂuencing the
performance of the malaria component of the DUAL IT L/M.
In summary, the DUAL IT L/M was found to be a highly
accurate and practical diagnostic test for VL in Uganda. The
malaria diagnostic component was not found to be useful.
Therefore, we introduced the DiaMed IT LEISH as a ﬁrst-line
test for patients presenting with clinical suspicion of VL at AH
in the ﬁrst trimester 2005. If an ongoing 3- to 6-month post-
study validation phase conﬁrms the ﬁndings of the present
study, the dipstick will replace the DAT for the diagnosis of VL
in this setting in Uganda. Because of the long persistence of
antibodies against rK39 antigen in the serum after treatment
(27), spleen puncture will remain necessary to conﬁrm the
diagnosis of relapse in patients with a previous history of VL
and a positive dipstick. The introduction of the dipstick in
more peripheral health centers, leading to an earlier diagnosis
and perhaps a better treatment outcome, should then be im-
plemented. The major remaining challenge is for the Ugandan
Ministry of Health to create and ensure a sustainable supply of
this diagnostic tool to AH.
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